Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

EMA

- PMLiVE

AstraZeneca and Daiichi Sankyo’s Enhertu shows significant improvements for lung cancer patients

Data showed a confirmed objective response rate of 53.8% in patients with HER2-mutant metastatic non-small cell lung cancer

- PMLiVE

AstraZeneca shares positive Tagrisso data in patients with EGFR-mutated lung cancer

Lung cancer is the leading cause of cancer death among both men and women

- PMLiVE

Amgen announces positive results for Lumakras colorectal cancer combination treatment

Results demonstrated a confirmed objective response rate of 30% and median progression free survival of 5.7 months

regeneron headquarters

Regeneron’s Libtayo shows promising results in phase 2 skin cancer trial

In the phase 2 trial, 50.6% of patients achieved the primary endpoint of complete pathologic response

Syapse and Genesis Research logos

Genesis Research and Syapse combine forces to offer RWE and data to oncology innovators

Genesis Research is delighted to announce a strategic partnership with Syapse®, combining the expertise and resources of both companies to better serve clients that are developing new oncology innovations.

Genesis Research Group

Advancing Precision Medicine in Oncology

Jerome Madison, Host of The Precision Medicine Podcast, shares his leadership lessons and tips for building and training new sales teams in the era of precision medicine. He also dives...

Impetus Digital

- PMLiVE

Moderna granted FDA authorisation for emergency use of BA.4/BA.5-targeting bivalent COVID-19 booster

The application was based on preclinical data and clinical trial data available from a phase 2/3 study evaluation of the company's BA.1 Omicron-targeting bivalent booster candidate

- PMLiVE

Novartis and Kaiku Health expand digital health monitoring partnership

The expansion aims to provide improved cancer care to a wider group of patients spanning multiple indications

- PMLiVE

Amgen’s Lumakras shows promising results for patients with non-small cell lung cancer

Results from the phase 3 trial demonstrated superiority over standard of care Docetaxel chemotherapy in KRAS G12C-mutated non-small cell lung cancer

- PMLiVE

Sanofi and Sobi’s efanesoctocog alfa granted FDA priority review for haemophilia A

Phase 3 results showed once-weekly doses provided clinically meaningful bleed protection for patients with haemophilia A

- PMLiVE

New study shows pioneering test for endometrial cancer could significantly reduce diagnosis time

The study findings have been published in the Journal of Clinical Oncology

- PMLiVE

Moderna seeks FDA Emergency Use Authorisation for BA.4/BA.5 COVID-19 booster

The application is based on preclinical data and clinical trial data available from a phase 2/3 study evaluation of the company's BA.1 Omicron-targeting bivalent booster candidate

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links